Page 6 - பல்கலைக்கழகம் ஆஃப் அலபாமா இல் பர்மிங்காம் மருத்துவமனை News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Published: Apr 23, 2021 LONDON and RALEIGH, N.C., April 23, 2021 (GLOBE NEWSWIRE) Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces data from a pilot study of a pressurized metered-dose inhaler (“pMDI”) formulation of ensifentrine showed that ensifentrine was safe and well tolerated in patients infected with SARS-CoV-2, the virus that causes COVID-19. The trial was not designed or sized to demonstrate clinical efficacy and no clinical efficacy benefit with ensifentrine treatment added on to standard of care was observed in the trial. One patient death was reported in the ensifentrine treatment group. “Overall, the patients in this study recovered exceptionally well, as the mortality rate in the study was much lower than aggregate data from the hospital would have suggested over the same time period,” commented Mike Wells, MD, a pulmonologist and Principal Investigator at the

United kingdomCity ofMike wellsKimberly minarovich michael barronVerona pharmaStrategic communicationsUniversity of alabama at birmingham hospitalInternational mediaUniversity of alabama at birminghamPrincipal investigatorChronic obstructive pulmonary diseaseLancet respir medKingdom telEuropean investor enquiriesEva haasAnnual report